Intracameral bevacizumab as an adjunct to trabeculectomy: A 1-year prospective, randomised study

British Journal of Ophthalmology

Volumn 98, Issue 1, 2014, Pages 73-78

  Vandewalle, Evelien ^a   Pinto, Luís Abegão ^b,c   Van Bergen, Tine ^d   Spielberg, Leigh ^e   Fieuws, Steffen ^f   Moons, Lieve ^d   Spileers, Werner ^a   Zeyen, Thierry ^a   Stalmans, Ingeborg ^a,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c Universidade de Lisboa   (Portugal)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e ROTTERDAM EYE HOSPITAL   (Netherlands)

^f KU LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PLACEBO;

ADJUVANT THERAPY; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRABECULECTOMY; TREATMENT FAILURE;

CLINICAL TRIAL; GLAUCOMA; WOUND HEALING;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TRABECULECTOMY;

EID: 84890570254     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303966     Document Type: Article

References (24)

1. Seibold LK, Sherwood MB, Kahook MY. Wound modulation after filtration surgery. Surv Ophthalmol 2012;57:530-50.
2. Cordeiro MF, Schultz GS, Ali RR, et al. Molecular therapy in ocular wound healing. Br J Ophthalmol 1999;83:1219-24.
3. Rai P, Kotecha A, Kaltsos K, et al . Changing trends in the incidence of bleb-related infection in trabeculectomy. Br J Ophthalmol 2012;96:971-5.
4. Mochizuki K, Jikihara S, Ando Y, et al. Incidence of delayed onset infection after trabeculectomy with adjunctive mitomycin C or 5-fluorouracil treatment. Br J Ophthalmol 1997;81:877-83.
5. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006;12:5018-22.
6. Wilgus TA, Ferreira AM, Oberyszyn TM, et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest 2008;88:579-90.
7. Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2009;50:5217-25.
8. O'Neill EC, Qin Q, Van Bergen NJ, et al. Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 2010;51:6524-32.
9. Tripathi RC, Li J, Tripathi BJ, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998;105:232-7.
10. Memarzadeh F, Varma R, Lin LT, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 2009;50:3233-7.
11. Van Bergen T, Vandewalle E, Van de Veire S, et al. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res 2011;93:689-99.
12. Grewal DS, Jain R, Kumar H, et al. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy: a pilot study. Ophthalmology 2008;115:2141-45.e2.
13. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20.
14. Vandewalle E, Van de Veire S, Renier C, et al . Trabeculectomy with or without anterior chamber maintainer and adjustable sutures. J Glaucoma Published Online First: 21 Aug 2012. doi:10.1097/IJG.0b013e318269806a
15. Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology 2010;117:1324-30.
16. Jurkowska-Dudzińska J, Kosior-Jarecka E, Zarnowski T. Comparison of the use of 5-fluorouracil and bevacizumab in primary trabeculectomy: results at 1 year. Clin Experiment Ophthalmol 2012;40:e135-42.
17. Sedghipour MR, Mostafaei A, Taghavi Y. Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma. Clin Ophthalmol 2011;5:797-800.
18. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807-13.
19. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol 2010;21:178-83.
20. Watanabe J, Sawaguchi S, Fukuchi T, et al. Effects of mitomycin C on the expression of proliferating cell nuclear antigen after filtering surgery in rabbits. Graefes Arch Clin Exp Ophthalmol 1997;235:234-40.
21. Schwartz AL, Van Veldhuisen PC, Gaasterland DE, et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. Am J Ophthalmol 1999;127:8-19.
22. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000;41:1181-5.
23. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000;41:1186-91.
24. Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev 2005;4:CD002897. doi:10.1002/14651858. CD002897.pub2